Shailesh Patel, MD
Pulmonary Disease · Schenectady, NYNPI 1720145246
Payments from drug & device makers
Across 270 payments — averaging $21.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Harmony Biosciences LLC$863
- AstraZeneca$685
- Sanofi$391
- Boehringer Ingelheim$337
- Jazz Pharmaceuticals Inc.$334
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,48694%
- Education$3686%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 66 | $1,272 |
| Harmony Biosciences LLC | 42 | $863 |
| AstraZeneca | 32 | $685 |
| Sanofi | 17 | $391 |
| Boehringer Ingelheim | 15 | $337 |
| Jazz Pharmaceuticals Inc. | 10 | $334 |
| Regeneron Healthcare Solutions, Inc. | 10 | $314 |
| Insmed, Inc. | 14 | $283 |
| Actelion Pharmaceuticals US, Inc. | 8 | $189 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $179 |
| Amgen | 7 | $142 |
| Grifols USA, LLC | 5 | $130 |
| Electromed, Inc. | 5 | $110 |
| Pfizer | 5 | $109 |
| Mallinckrodt Hospital Products Inc. | 2 | $59 |
| Lilly USA, LLC | 2 | $54 |
| Verona Pharma, Inc. | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Itamar Medical Inc | 1 | $33 |
| Genentech USA, Inc. | 2 | $27 |
| Vifor Pharma, Inc. | 1 | $27 |
| Circassia Inc. | 2 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Merck | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| United Therapeutics Corporation | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Novartis | 1 | $18 |
| Philips North America LLC | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$120
How this compares
$5,854 in reported general payments places this provider in the 70th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 45 | $732,869 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 383 | $448,309 |
| EsbrietPirfenidone | 12 | $123,383 |
| Breo ElliptaFluticasone/Vilanterol | 108 | $78,436 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 64 | $55,769 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $45,440 |
| Advair HfaFluticasone Propion/Salmeterol | 59 | $34,930 |
| Pirfenidone | 35 | $25,089 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 136 | $22,588 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 18 | $15,833 |
| Mycophenolate Mofetil | 41 | $15,358 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $12,930 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $11,039 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 272 | $9,431 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 25 | $8,142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $337 | $732,86945 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,272 | $593,552574 claims |
| Genentech USA, Inc.Esbriet | $27 | $123,38312 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $685 | $74,20382 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Schenectady
- Ahmed KhanSchenectady$453K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.